Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa
Miguel Marchena(Centro de Investigaciones Biológicas Margarita Salas), Enrique J. de la Rosa(Instituto de Salud Carlos III), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Josefa Zaldívar-Díez(Centro de Investigaciones Biológicas Margarita Salas), Beatriz Villarejo‐Zori(Centro de Investigaciones Biológicas Margarita Salas), Carmen Gil(Instituto de Salud Carlos III), Catalina Hernández‐Sánchez(Centro de Investigaciones Biológicas Margarita Salas)
Cited by 25
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293